While uncommon, the prognosis for hairy cell leukemia (HCL) is quite favorable, explains Martin S. Tallman, MD, adding that most patients respond to the standard of care,
Martin S. Tallman, MD
cladribine, with relapse rates between 25% and 35%.However, as the biology of HCL continues to be further understood, markers such as BRAF mutations has opened the door to new therapeutic strategies for patients.
In an interview with OncLive, Tallman, c
hief of Leukemia Service, Cassidy Family Endowed Faculty Chair, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses the biology, prognosis, and current treatment options available in HCL.
... to read the full story